The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose?

Mark F McCarty, James J DiNicolantonio, Mark F McCarty, James J DiNicolantonio

No abstract available

Keywords: Diabetes; Fructose; Glycine; Sucrose; Sugar.

Figures

Figure 1
Figure 1
Hepatic effects of fructose.
Figure 2
Figure 2
Hepatoprotective mechanisms of glycine.

References

    1. Zhong Z, Wheeler MD, Li X, et al. L-glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care 2003;6:229–40
    1. Ikejima K, Qu W, Stachlewitz RF, et al. Kupffer cells contain a glycine-gated chloride channel. Am J Physiol 1997;272(6 Pt 1):G1581–6
    1. Wheeler M, Stachlewitz RF, Yamashina S, et al. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production. FASEB J 2000;14:476–84
    1. Wheeler MD, Thurman RG. Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine. Am J Physiol 1999;277(5 Pt 1):L952–9
    1. Froh M, Thurman RG, Wheeler MD. Molecular evidence for a glycine-gated chloride channel in macrophages and leukocytes. Am J Physiol Gastrointest Liver Physiol 2002;283:G856–63
    1. Yamashina S, Konno A, Wheeler MD, et al. Endothelial cells contain a glycine-gated chloride channel. Nutr Cancer 2001;40:197–204
    1. Schemmer P, Zhong Z, Galli U, et al. Glycine reduces platelet aggregation. Amino Acids 2013;44:925–31
    1. Rose ML, Madren J, Bunzendahl H, et al. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis 1999;20:793–8
    1. Yin M, Ikejima K, Arteel GE, et al. Glycine accelerates recovery from alcohol-induced liver injury. J Pharmacol Exp Ther 1998;286:1014–19
    1. Rose ML, Cattley RC, Dunn C, et al. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis 1999;20:2075–81
    1. Yin M, Zhong Z, Connor HD, et al. Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo. Am J Physiol Renal Physiol 2002;282:F417–23
    1. Wheeler MD, Rose ML, Yamashima S, et al. Dietary glycine blunts lung inflammatory cell influx following acute endotoxin. Am J Physiol Lung Cell Mol Physiol 2000;279:L390–8
    1. Li X, Bradford BU, Wheeler MD, et al. Dietary glycine prevents peptidoglycan polysaccharide-induced reactive arthritis in the rat: role for glycine-gated chloride channel. Infect Immun 2001;69:5883–91
    1. Senthilkumar R, Nalini N. Glycine prevents hepatic fibrosis by preventing the accumulation of collagen in rats with alcoholic liver injury. Pol J Pharmacol 2004;56:121–8
    1. Ham DJ, Murphy KT, Chee A, et al. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr 2014;33:448–58
    1. Wang W, Wu Z, Dai Z, et al. Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids 2013;45:463–77
    1. Zhong X, Li X, Qian L, et al. Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats. J Biomed Res 2012;26:346–54
    1. Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004;84:1051–95
    1. McCarty MF, Barroso-Aranda J, Contreras F. The hyperpolarizing impact of glycine on endothelial cells may be anti-atherogenic. Med Hypotheses 2009;73:263–4
    1. Ruiz-Meana M, Pina P, Garcia-Dorado D, et al. Glycine protects cardiomyocytes against lethal reoxygenation injury by inhibiting mitochondrial permeability transition. J Physiol 2004;558(Pt 3):873–82
    1. Busse R, Luckhoff A, Mulsch A. Cellular mechanisms controlling EDRF/NO formation in endothelial cells. Basic Res Cardiol 1991;86(Suppl 2):7–16
    1. Sohn HY, Keller M, Gloe T, et al. The small G-protein Rac mediates depolarization-induced superoxide formation in human endothelial cells. J Biol Chem 2000;275:18745–50
    1. Matsuzaki I, Chatterjee S, Debolt K, et al. Membrane depolarization and NADPH oxidase activation in aortic endothelium during ischemia reflect altered mechanotransduction. Am J Physiol Heart Circ Physiol 2005;288:H336–43
    1. McCabe RD, Bakarich MA, Srivastava K, et al. Potassium inhibits free radical formation. Hypertension 1994;24:77–82
    1. Young DB, Lin H, McCabe RD. Potassium's cardiovascular protective mechanisms. Am J Physiol 1995;268(4 Pt 2):R825–37
    1. McCarty MF. Endothelial membrane potential regulates production of both nitric oxide and superoxide––a fundamental determinant of vascular health. Med Hypotheses 1999;53:277–89
    1. Hasegawa S, Ichiyama T, Sonaka I, et al. Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells. Clin Exp Immunol 2012;167:269–74
    1. Sekhar RV, Patel SG, Guthikonda AP, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr 2011;94:847–53
    1. Ramakrishnan S, Sulochana KN. Decrease in glycation of lens proteins by lysine and glycine by scavenging of glucose and possible mitigation of cataractogenesis. Exp Eye Res 1993;57:623–8
    1. Ramakrishnan S, Sulochana KN, Punitham R. Free lysine, glycine, alanine, glutamic acid and aspartic acid reduce the glycation of human lens proteins by galactose. Indian J Biochem Biophys 1997;34:518–23
    1. Carvajal SG, Medina SR, Juarez E, et al. Effect of glycine on hemoglobin glycation in diabetic patients. Proc West Pharmacol Soc 1999;42:31–2
    1. Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, et al. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J Endocrinol Invest 2008;31:694–9
    1. Carvajal SG, Juarez E, Ramos MG, et al. Inhibition of hemoglobin glycation with glycine in induced diabetes mellitus in rats. Proc West Pharmacol Soc 1999;42:35–6
    1. Alvarado-Vasquez N, Lascurain R, Ceron E, et al. Oral glycine administration attenuates diabetic complications in streptozotocin-induced diabetic rats. Life Sci 2006;79:225–32
    1. Lezcano MD, Teran OL, Carvajal SG, et al. Effect of glycine on the immune response of the experimentally diabetic rats. Rev Alerg Mex 2006;53:212–16
    1. Bahmani F, Bathaie SZ, Aldavood SJ, et al. Glycine therapy inhibits the progression of cataract in streptozotocin-induced diabetic rats. Mol Vis 2012;18:439–48
    1. Munoz-Carlin ML, Rodriguez-Moctezuma JR, Gomez Latorre JG, et al. [Effects of glycine on auditory evoked potentials among diabetic patients with auditory pathway neuropathy]. Rev Med Chil 2010;138:1246–52
    1. El HM, Perez I, Zamora J, et al. Glycine intake decreases plasma free fatty acids, adipose cell size, and blood pressure in sucrose-fed rats. Am J Physiol Regul Integr Comp Physiol 2004;287:R1387–93
    1. Ruiz-Ramirez A, Ortiz-Balderas E, Cardozo-Saldana G, et al. Glycine restores glutathione and protects against oxidative stress in vascular tissue from sucrose-fed rats. Clin Sci (Lond) 2014;126:19–29
    1. Diaz-Flores M, Cruz M, Duran-Reyes G, et al. Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure. Can J Physiol Pharmacol 2013;91:855–60
    1. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119:1322–34
    1. Zhang YH, An T, Zhang RC, et al. Very high fructose intake increases serum LDL-cholesterol and total cholesterol: a meta-analysis of controlled feeding trials. J Nutr 2013;143:1391–8
    1. Basaranoglu M, Basaranoglu G, Sabuncu T, et al. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013;19:1166–72
    1. Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol 2013;24:198–206
    1. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase cepsilon and hepatic insulin resistance. Cell Metab 2012;15:574–84
    1. Chan SM, Sun RQ, Zeng XY, et al. Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 2013;62:2095–105
    1. Boren J, Rustaeus S, Wettesten M, et al. Influence of triacylglycerol biosynthesis rate on the assembly of apoB-100-containing lipoproteins in Hep G2 cells. Arterioscler Thromb 1993; 13:1743–54
    1. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 2003;111:246–50
    1. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities––the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374–81
    1. Kinote A, Faria JA, Roman EA, et al. Fructose-induced hypothalamic AMPK activation stimulates hepatic PEPCK and gluconeogenesis due to increased corticosterone levels. Endocrinology 2012;153:3633–45
    1. Gameiro A, Reimann F, Habib AM, et al. The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol 2005;569(Pt 3):761–72
    1. Karamanlis A, Chaikomin R, Doran S, et al. Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. Am J Clin Nutr 2007;86:1364–8
    1. Rubio IG, Castro G, Zanini AC, et al. Oral ingestion of a hydrolyzed gelatin meal in subjects with normal weight and in obese patients: postprandial effect on circulating gut peptides, glucose and insulin. Eat Weight Disord 2008;13:48–53
    1. Gannon MC, Nuttall FQ, Neil BJ, et al. The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects. Metabolism 1988;37:1081–8
    1. Gannon MC, Nuttall JA, Nuttall FQ. The metabolic response to ingested glycine. Am J Clin Nutr 2002;76:1302–7
    1. Hauge-Evans AC, King AJ, Carmignac D, et al. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009;58:403–11
    1. De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 2010;11:543–53
    1. Li C, Liu C, Nissim I, et al. Regulation of glucagon secretion in normal and diabetic human islets by gamma-hydroxybutyrate and glycine. J Biol Chem 2013;288:3938–51
    1. Muller WA, Aoki TT, Cahill GF., Jr Effect of alanine and glycine on glucagon secretion in postabsorptive and fasting obese man. J Clin Endocrinol Metab 1975;40:418–25
    1. Ben-Shlomo S, Zvibel I, Shnell M, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011;54:1214–23
    1. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011;31:1285–97
    1. Lee J, Hong SW, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS ONE 2012;7:e31394.
    1. Louet JF, Hayhurst G, Gonzalez FJ, et al. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J Biol Chem 2002;277:37991–8000
    1. Lane MD, Watkins PA, Meredith MJ. Hormonal regulation of acetyl-CoA carboxylase activity in the liver cell. CRC Crit Rev Biochem 1979;7:121–41
    1. Hayden LJ, Cohen S, Levin K, et al. Comparison of glucagon, cAMP, and cGMP effects on lipogenesis in hepatocytes. Can J Biochem Cell Biol 1983;61:207–13
    1. Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012;302:G225–35
    1. Sharma S, Mells JE, Fu PP, et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE 2011;6:e25269.
    1. Lee J, Hong SW, Rhee EJ, et al. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 2012;36:262–7
    1. Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 2012;7:e50117.
    1. Olaywi M, Bhatia T, Anand S, et al. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 2013;12:584–8
    1. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009;196:81–98
    1. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008;57:306–14
    1. Andreelli F, Foretz M, Knauf C, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006;147:2432–41
    1. Horike N, Sakoda H, Kushiyama A, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J Biol Chem 2008;283:33902–10
    1. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749–57
    1. Patel V, Joharapurkar A, Dhanesha N, et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol 2013;91:1009–15
    1. Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon co-agonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 2014;63:1422–7
    1. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2013;28:262–74
    1. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007;41:51–60
    1. Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 2013
    1. Fields AV, Patterson B, Karnik AA, et al. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol 2009;32:236–43
    1. Ravassa S, Zudaire A, Diez J. Glucagon-like peptide 1 and cardiac cell survival. Endocrinol Nutr 2012;59:561–9
    1. Angeli FS, Shannon RP. Incretin based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol 2014;221:T17–30
    1. Clarke SJ, McCormick LM, Dutka DP. Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol 2014;13:12.
    1. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
    1. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013;31:238–49
    1. Yamashina S, Ikejima K, Enomoto N, et al. Glycine as a therapeutic immuno-nutrient for alcoholic liver disease. Alcohol Clin Exp Res 2005;29(11 Suppl):162S–5S
    1. Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094–104
    1. Spruss A, Kanuri G, Stahl C, et al. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012;92:1020–32
    1. Zhu ML, Liu J, Liu YL, et al. [Activation of Kupffer cell and related signal pathway proteins in the liver of high fat and high fructose diet induced NAFLD mice]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2013;27:325–7
    1. Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007;293:C584–96
    1. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008;295:F1134–41
    1. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011;60:1258–69
    1. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170–80
    1. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885–92
    1. Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102–10
    1. Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 2013;8:e56864.
    1. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014;16:15–24
    1. Guthikonda S, Sinkey C, Barenz T, et al. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003;107:416–21
    1. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746–51
    1. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619–24
    1. Harzand A, Tamariz L, Hare JM. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 2012;18:179–82
    1. Waring WS, Adwani SH, Breukels O, et al. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 2004;90:155–9
    1. Waring WS, McKnight JA, Webb DJ, et al. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia 2007;50:2572–9
    1. Waring WS, McKnight JA, Webb DJ, et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006;55:3127–32
    1. Spitsin S, Markowitz CE, Zimmerman V, et al. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. J Hum Hypertens 2010;24:359–62
    1. Lyngdoh T, Vuistiner P, Marques-Vidal P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS ONE 2012;7:e39321.
    1. Pfister R, Barnes D, Luben R, et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia 2011;54:2561–9
    1. Oikonen M, Wendelin-Saarenhovi M, Lyytikainen LP, et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. Atherosclerosis 2012;223:497–503
    1. Dai X, Yuan J, Yao P, et al. Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. Eur J Epidemiol 2013;28:669–76
    1. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262.
    1. Parsa A, Brown E, Weir MR, et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 2012;81:502–7
    1. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008–11
    1. Shen C, Guo Y, Luo W, et al. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 2013;40:73–9
    1. Gonzalez-Aramburu I, Sanchez-Juan P, Jesus S, et al. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. Mov Disord 2013;28:1737–40

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever